Wall Street brokerages expect that Eagle Pharmaceuticals Inc (NASDAQ:EGRX) will post sales of $46.40 million for the current quarter, Zacks Investment Research reports. Two analysts have issued estimates for Eagle Pharmaceuticals’ earnings. The highest sales estimate is $48.30 million and the lowest is $44.50 million. Eagle Pharmaceuticals reported sales of $41.15 million in the same quarter last year, which indicates a positive year-over-year growth rate of 12.8%. The firm is scheduled to issue its next earnings results on Tuesday, November 10th.
On average, analysts expect that Eagle Pharmaceuticals will report full year sales of $190.91 million for the current financial year, with estimates ranging from $186.90 million to $194.91 million. For the next fiscal year, analysts expect that the business will post sales of $226.97 million, with estimates ranging from $205.70 million to $248.24 million. Zacks’ sales averages are an average based on a survey of sell-side analysts that that provide coverage for Eagle Pharmaceuticals.
Eagle Pharmaceuticals (NASDAQ:EGRX) last posted its earnings results on Monday, August 10th. The specialty pharmaceutical company reported $0.57 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.24 by $0.33. The company had revenue of $41.94 million during the quarter, compared to analyst estimates of $37.46 million. Eagle Pharmaceuticals had a positive return on equity of 4.11% and a negative net margin of 2.54%.
Several research firms have recently commented on EGRX. ValuEngine cut shares of Eagle Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Thursday. BidaskClub upgraded shares of Eagle Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Tuesday. Finally, Zacks Investment Research raised Eagle Pharmaceuticals from a “strong sell” rating to a “hold” rating in a report on Tuesday, September 15th. Four analysts have rated the stock with a hold rating and one has given a buy rating to the company. The company presently has an average rating of “Hold” and a consensus target price of $53.67.
A number of hedge funds have recently made changes to their positions in the stock. Canada Pension Plan Investment Board bought a new stake in Eagle Pharmaceuticals in the second quarter worth about $34,000. Bank of Montreal Can lifted its stake in Eagle Pharmaceuticals by 2,426.5% during the second quarter. Bank of Montreal Can now owns 1,238 shares of the specialty pharmaceutical company’s stock valued at $58,000 after purchasing an additional 1,189 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank lifted its stake in Eagle Pharmaceuticals by 114.1% during the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,055 shares of the specialty pharmaceutical company’s stock valued at $99,000 after purchasing an additional 1,095 shares during the last quarter. Caxton Associates LP bought a new stake in Eagle Pharmaceuticals during the first quarter worth approximately $210,000. Finally, Commonwealth of Pennsylvania Public School Empls Retrmt SYS grew its position in Eagle Pharmaceuticals by 48.4% in the first quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 5,090 shares of the specialty pharmaceutical company’s stock worth $234,000 after buying an additional 1,660 shares during the last quarter. 95.38% of the stock is owned by institutional investors and hedge funds.
NASDAQ EGRX traded down $1.35 during trading hours on Wednesday, hitting $41.72. The company had a trading volume of 166,081 shares, compared to its average volume of 176,694. The company has a quick ratio of 3.97, a current ratio of 4.16 and a debt-to-equity ratio of 0.16. The firm has a market cap of $567.68 million, a P/E ratio of -126.42 and a beta of 0.77. Eagle Pharmaceuticals has a fifty-two week low of $33.80 and a fifty-two week high of $64.94. The business has a fifty day simple moving average of $40.01 and a 200-day simple moving average of $46.14.
Eagle Pharmaceuticals Company Profile
Eagle Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on developing and commercializing injectable products primarily in the critical care and oncology areas in the United States. The company offers Argatroban, an anti-coagulant thrombin inhibitor for heparin-induced thrombocytopenia; Ryanodex for malignant hyperthermia; Bendeka for chronic lymphocytic leukemia (CLL) and indolent B-cell non-Hodgkin's lymphoma (NHL); and Belrapzo, a chemotherapeutic agent for CLL and Indolent NHL.
Featured Article: Capital Gains Distribution
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Eagle Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eagle Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.